Hadean Ventures announces final closing of Hadean Capital I, placing the fund amongst the largest new life science fund launches in Europe at €71m
- One of the largest life science VC launches in Europe
- Supported by blue chip institutional and private, European and US-based investors
- Three investments completed from the new fund
06.07.2019, Oslo, Stockholm – Hadean Ventures announced today the final closing of Hadean Capital I at €71m. The fund is supported by a consortium of blue chip European and US-based fund investors. The strategy has a particular focus on regions of Europe harbouring world class scientific communities and a booming start-up environment, yet are under-served from a venture capital perspective, especially the Nordics.
Ingrid Teigland Akay, Managing Partner of Hadean Ventures, says: “We are extremely pleased with the strong support we have received from a broad base of highly experienced institutional and private fund investors. This is a vote of confidence in our strategy, focusing on regions of Europe with high potential within life sciences, yet very few specialized venture investors. I believe we are uniquely positioned to leverage this opportunity with an experienced team and a strong presence in the Nordic region.”
Hadean Ventures has so far invested into three companies, Stockholm-based specialty pharma company Attgeno AB, Trondheim-based ultrasound/deep learning medtech company Nisonic AS and Lund-based SAGA Diagnostics AB, a player in the liquid biopsy space.
Walter Stockinger, Managing Partner of Hadean Ventures, adds “we are highly encouraged by the exceptionally strong deal flow we have from across the Nordic region and beyond. We see it as a product of the maturing ecosystem that increasingly is able to leverage a longstanding tradition for scientific excellence and significant investments in basic research. In combination with a surge in entrepreneurship, this has created an outstanding environment for life science start-ups.”
“I am delighted that our €20 million commitment will help the team to execute on its strategy with a particular focus on the Nordics and thereby target growth and value creation in the life science industry, which in our view holds substantial promise”, says Peder Hasslev, CEO of Saminvest AB
“We congratulate Hadean Ventures with their final close. Argentum invests in the fund because we believe in the health sector’s growth potential and Hadean Ventures’ ability to find and develop the companies that solve tomorrow’s health challenges”, says CEO of Argentum, Joachim Høegh-Krohn.
About Hadean Ventures
Hadean Ventures (hadeanventures.com) is a European life science fund manager that invests in life science companies across Europe with a particular focus on the Nordic region. Hadean Ventures is managing funds backed by leading private and institutional investors including Saminvest and Argentum. Hadean Ventures has offices in Oslo and Stockholm and collaborates with world-class academic institutions and start-up hubs across the region.